Skip to main
COYA

COYA Stock Forecast & Price Target

COYA Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Coya Therapeutics Inc. has demonstrated a positive trajectory in its clinical development, notably through statistically significant increases in Treg numbers and suppressive function within just two weeks, sustaining these enhancements throughout a 22-week treatment period. The successful proof of concept study for COYA 302 in frontotemporal dementia, which showed robust regulatory T cell engagement and cognitive stability, strengthens the company’s positioning as a potential leader in addressing neurodegenerative diseases with high unmet needs. Additionally, the favorable safety profile observed in clinical trials, combined with recent FDA clearance, underscores the company's advancing Treg-focused therapeutic platform.

Bears say

Coya Therapeutics Inc faces significant risks that could adversely affect its financial performance and valuation, primarily related to potential obsolescence of its therapies due to advancements in treatment methods for neurodegenerative, autoimmune, and metabolic diseases. The company also struggles with the adequacy of its intellectual property protection, which poses further risks of costly legal challenges that could divert resources and financial focus. Additionally, Coya's ongoing cash burn necessitates the likelihood of raising additional capital for operations, amplifying concerns about its long-term financial stability and viability in the competitive biotechnology landscape.

COYA has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Coya Therapeutics Inc (COYA) Forecast

Analysts have given COYA a Strong Buy based on their latest research and market trends.

According to 5 analysts, COYA has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Coya Therapeutics Inc (COYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.